Skip to content

Effects of targeting Stellate Ganglion activity with different doses of dexmedetomidine on postoperative sleep disturbances in elderly patients undergoing thoracoscopic lobectomy

Effects of targeting Stellate Ganglion activity with different doses of dexmedetomidine on postoperative sleep disturbances in elderly patients undergoing thoracoscopic lobectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112081
Enrollment
Unknown
Registered
2025-11-10
Start date
2025-11-10
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative sleep disorders

Interventions

Group L:Ultrasound-guided injection of 5 ml mixture of dexmedetomidine (0.25 µg/kg, Enhua Pharma) in saline near the operative-side stellate ganglion preoperatively.
Group M:Ultrasound-guided injection of 5 ml mixture of dexmedetomidine (0.5 µg/kg, Enhua Pharma) in saline near the operative-side stellate ganglion preoperatively.
Group H:Ultrasound-guided injection of 5 ml mixture of dexmedetomidine (0.75 µg/kg, Enhua Pharma) in saline near the operative-side stellate ganglion preoperatively.
Group C:Ultrasound-guided injection equivalent dose of 5 ml 0.9% saline near the operative-side stellate ganglion preoperatively.

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 60-79 years; 2. ASA classification II-III; 3. Scheduled for thoracoscopic lobectomy; 4. Patients who sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Individuals with contraindications to regional puncture( infections around the puncture site, and coagulation disorders: such as PLT1.5); 2. Individuals who have experienced any cerebrovascular accidents within the past 3 months, such as stroke or transient ischemic attack (TIA); 3. Patients with language communication disorders or mental disorders; 4. Patients with severe bradycardia or II-III degree atrioventricular block; 5. Individuals with contraindications to experimental drugs and other anesthetics; 6. Identify patients with sleep disorder prior to surgery.

Design outcomes

Primary

MeasureTime frame
Incidence of sleep disturbances within 3 days after surgery;

Secondary

MeasureTime frame
Sleep Quality Numeric Rating Scale (NRS) scores on the morning of postoperative days 1, 2, 3 and 7;Pittsburgh Sleep Quality Index (PSQI) score;Postoperative sleep (sleep duration, and the duration and proportion of deep sleep, light sleep, REM sleep);Hospital Anxiety and Depression Scale score;Pain VAS score within the first 3 postoperative days;Incidence of intraoperative hypotension, bradycardia, hypertension and tachycardia.;Postoperative adverse reactions (respiratory depression, nausea and vomiting, hypotension, bradycardia, etc.);Intraoperative hemodynamic indexes;Hospital stay, LOS;Intraoperative Heart Rate Variability;Athens Insomnia Scale (AIS) scores on the morning of postoperative days 1, 2, 3 and 7;

Countries

China

Contacts

Public ContactCheng Xinqi

The First Affiliated Hospital of Anhui Medical University

ay_mz_cheng@126.com+86 139 6501 5671

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026